<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="with IC50 values of around 50 and 6 Î¼M, respectively." exact="Glycine" post="linkage of peptide P4 (residue 22â€&quot;47) with an ACE2"/>
 <result pre="SARS-CoV pseudotyped virus, cytotoxicity data is not available to date.66" exact="Chloroquine" post="(4) currently has applications for malaria and amoebiasis treatment."/>
 <result pre="malaria and amoebiasis treatment. Interestingly, Nichol et al. showed that" exact="chloroquine" post="could also block the interaction of RBD of SARS-CoV"/>
 <result pre="and a CC50 &amp;gt; 100 Î¼M in Vero E6 cells.68" exact="Chloroquine" post="possibly increases endosomal pH required for virus/cell fusion as"/>
 <result pre="the affinity of SARS-CoV/SARS-CoV-2 to ACE2. Besides its antiviral activity," exact="chloroquine" post="may synergistically enhance its antiviral effect with immune-modulating activity"/>
 <result pre="its antiviral effect with immune-modulating activity in vivo.68 At present," exact="chloroquine" post="is carried out in clinical research in China for"/>
 <result pre="of chloroquine, which shares the same mechanism of action as" exact="chloroquine" post="but displays a more tolerable safety profile.70 Yao et"/>
 <result pre="pseudotyped viruses when treated with a combination of (23,25)trans-epoxysuccinyl- l-leucylamindo-3-methylbutane" exact="ethyl ester" post="(EST, a cathepsin inhibitor) and 22. The results suggested"/>
 <result pre="of 75 Î¼M in HEK-293T cells. Furthermore, when cathepsin inhibitor" exact="camostat" post="was used in combination with 23, a significant inhibition"/>
 <result pre="23, a significant inhibition in infectivity was characterized compared to" exact="camostat" post="alone.20 Recently, Bestle et al., showed that the potent"/>
 <result pre="Targeting Host Factors and Unknown Targets Machamer et al. found" exact="imatinib" post="(28), an Abelson kinase signaling pathway inhibitor that could"/>
 <result pre="effects in Vero cells at 100 Î¼M.123,124 Another Abl inhibitor," exact="dasatinib" post="(29), was active against both MERS-CoV and SARS-CoV, with"/>
 <result pre="CaoR.; ZhangL.; YangX.; LiuJ.; XuM.; ShiZ.; HuZ.; ZhongW.; XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="in Vitro. Cell Res.2020, 30, 269â€&quot;271. 10.1038/s41422-020-0282-0.32020029 GaoJ.; TianZ.; YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="D.; ParkeA. L.; Clifford-RashotteM.; KeanW. F.Therapy and pharmacological properties of" exact="hydroxychloroquine" post="and chloroquine in treatment of systemic lupus erythematosus, rheumatoid"/>
 <result pre="L.; Clifford-RashotteM.; KeanW. F.Therapy and pharmacological properties of hydroxychloroquine and" exact="chloroquine" post="in treatment of systemic lupus erythematosus, rheumatoid arthritis and"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.2020, ciaa23710.1093/cid/ciaa237.32150618 ChenC.; WangF.; LinC.Chronic" exact="hydroxychloroquine" post="use associated with qt prolongation and refractory ventricular arrhythmia."/>
 <result pre="e80â€&quot;e82. 10.1016/j.ijcard.2007.04.055.17590456 YaylaliS. A.; SadigovF.; ErbilH.; EkinciA.; AkcakayaA. A.Chloroquine and" exact="hydroxychloroquine" post="retinopathy-related risk factors in a turkish cohort. Int. Ophthalmol.2013,"/>
</results>
